Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rewiring the brain to silence chronic pain — a bold psychological therapy is put to the test

NCT ID NCT07724808

Symptom relief Sponsor: Ben-Gurion University of the Negev Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether pain reprocessing therapy (PRT) — a brief psychological treatment that combines education, cognitive restructuring, and body-focused techniques — can reduce chronic pain. Adults with persistent pain lasting over three months are randomly assigned to full PRT, a version without the somatic component, or usual care. Researchers use brain scans, EEG, and wearable monitors to track changes and identify who might benefit most.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pain reprocessing therapy (PRT), a psychological intervention combining psychoeducation, cognitive restructuring, and somatic elements
What this could lead to
If it works, this could point toward a drug-free, personalized treatment for chronic pain that targets the brain's role in pain.
What could go wrong
This is a relatively small, early-stage trial. The therapy may not work for everyone, and benefits could be modest or short-lived.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 20-70 years * Chronic pain lasting over 3 months, including chronic pain conditions such as fibromyalgia and complex regional pain syndrome (CRPS) * Average pain intensity ≥4 on a 0-10 scale * Stable medication regimen for at least 4 weeks prior to treatment initiation * Hebrew language fluency * Provision of informed consent, including consent for video recordings Exclusion Criteria: * Current participation in other pain-related psychotherapy * Pregnancy * Substance abuse, including deviations from prescribed medication use * Change in medication or dosage in the 4 weeks preceding treatment * Diagnosed active cancer * Dementia * Severe depression (BDI-II score \> 29) * Moderate cognitive impairment based on the Montreal Cognitive Assessment (MoCA) * Current or past diagnosis of schizophrenia, psychosis, bipolar disorder, multiple personality disorder, or dissociative identity disorder * Inability to undergo MRI as determined by MRI safety screening (e.g., claustrophobia, metal in body such as vascular clips, pacemakers, or certain cochlear implants)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome complex regional pain syndrome fibromyalgia NF2-related schwannomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Full PRT Partial PRT (non somtic) Treatment as usual

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ben-Gurion University of the Negev

    Beersheba, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.